Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
The Kinneret (Sea of Galilee) has ended March 2026 just above the bottom red line following heavy rainfall over...
Crude oil prices saw considerable volatility last week. Brent crude oil futures on the Intercontinental Exchange (ICE) ($105.30/barrel) was down 6.1...
The war in Iran is “incomparable” with any past oil shock in both its scale and its wide-ranging impact on...
Eternal shares on Friday rose 3% from the day's low of Rs 230.10 on the NSE to scale the day's...
A haunting whale song discovered on decades-old audio equipment could open up a new understanding of how the huge animals communicate, according...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
